H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed (NASDAQ:INSM) on Thursday, setting a price target of $52, which is approximately 77.53% above the present share price of $29.29.
Fein expects Insmed to post earnings per share (EPS) of -$0.74 for the second quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Insmed, with an average price target of $43.
The analysts price targets range from a high of $52 to a low of $35.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $36.86 million and a net profit of -$60.36 million. The company's market cap is $2.88 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 13.6% and a 48.43% success rate.
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.